Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
Are you Eligible? (Inclusion Criteria)
Inclusion Criteria:
- Pathologically confirmed diagnosis of one of any solid tumor
- Metastatic disease
- ECOG performance status ≤2
Exclusion Criteria:
- Known and confirmed diagnosis of Interstitial Lung Disease
- Clinically significant GI disorders, including history of small bowel obstruction unless the obstruction was a surgically treated remote episode
- HIV-positive patients on combination antiretroviral therapy
- High risk of seizures
Specialty Area(s)
Pancreas